Fevipiprant vs Minoxidil

Fevipiprant wins for diversifying mechanism against PGD2-driven follicle inhibition, oral convenience, and synergy in advanced multi-agent hair stacks where androgen suppression alone is maxed out.

Minoxidil wins for sheer regrowth efficacy, proven outcomes, universal availability (topical and oral), and a decades-deep safety track record backing real-world hair retention across scenarios. Minoxidil's benefits are consistent and reproducible; fevipiprant remains experimental, with efficacy unproven in AGA.

Pick Fevipiprant if:

• The protocol is targeting the PGD2/DP2 axis specifically (e.g., in a fin/dut + minox stack, to address androgen resistance).
• Other avenues (5-AR inhibitors, AR antagonists, minoxidil) are maxed and additional regrowth is being pursued via new mechanism.
• There is a biochemical or mechanistic interest in DP2 antagonism or documented PGD2-driven hair loss.
• Experimentation in a research context is acceptable, and the investigator is prepared for an unclear efficacy profile.
• Side-effect mitigation is prioritized (fevipiprant's profile in asthma trials is relatively mild vs. other oral agents).

Pick Minoxidil if:

• Maximizing hair regrowth in androgenetic alopecia with a gold-standard, proven option is the goal.
• Sourcing, cost, and ease of use (topical or oral) are priorities.
• The research goal includes immediate, visible effects within 3–6 months and long-term sustainability with continued administration.
• A reliable backbone for holding or regrowing density is required (minoxidil stacks with both antiandrogens and novel agents).
• A protocol favoring well-documented outcomes and manageable, well-understood side effects is preferred.